Synageva, Mitsubishi extend deal on protein drugs for rare disease

04/4/2012 | Genetic Engineering & Biotechnology News

Mitsubishi Tanabe Pharma and Synageva BioPharma will jointly develop a second therapeutic protein for an orphan disease using the latter's protein expression platform as part of their expanded rare-disease deal. Synageva will receive $9 million in upfront fees and reimbursement for development costs, plus potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID